低剂量,基于体重的皮下注射埃诺沙巴林协议在复发性动脉静脉接入血栓形成中的有效性和安全性
Chye Chung Gan1,2, Ru Yu Tan1,3, May Anne Cheong3,4
1Department of Renal Medicine, Singapore General Hospital, Singapore.
The journal of vascular access
|September 20, 2023
概括
短期的低剂量皮下注射埃诺沙巴林 (SEP) 方案有效地维持了复发性血栓瘤患者的动脉静脉 (AV) 接入通透性. 这种安全的血栓预防显著改善了无血栓的生存率,减少了与接触有关的并发症.
科学领域:
- 血管外科 血管外科
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性血栓形成是影响动脉静脉 (AV) 接入通透性的重大并发症.
- 保持AV接入功能对于需要血液透析的患者至关重要.
- 现有的血栓预防策略可能在治疗复发性静脉门血栓症方面存在局限性.
研究的目的:
- 评估一种新的短期,低剂量,基于体重的皮下注射埃诺沙巴林 (SEP) 协议的安全性和有效性.
- 评估SEP对在患有复发性血栓瘤的患者中保持AV通道通透性的影响.
- 为了确定SEP是否可以作为一种可行的AV接入的血栓预防方法.
主要方法:
- 对25名复发性AV接入血栓瘤患者的前性随访,这些患者在血栓切除术后接受了SEP治疗.
- 基于体重的皮下注射埃诺沙巴林剂量 (0.64 ± 0.1 mg/kg/天) 平均持续时间为30天.
- 卡普兰-梅尔分析,以比较无血栓性存活率在SEP之前和之后的采用,并对混因素进行调整.
主要成果:
- 施用SEP导致平均无血栓性存活时间从27.3天显著增加到183.5天 (p < 0.001).
- SEP被确定为与较长的无血栓性通透率相关的重要独立因素 (HR 0.166,p < 0.001).
- 只有一个患者经历了轻微的出血,这表明了有利的安全性.
结论:
- 皮下注射埃诺沙巴林协议 (SEP) 是一种可行且安全的血栓预防策略.
- 在患有复发性血栓瘤的患者中,SEP显著改善了AV接入的无血栓穿透性.
- 该协议提供了一种有希望的方法来增强AV接入的寿命和功能.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
747
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
747
01:30Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
01:27Pulmonary Embolism III: Nursing Management
15
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
15
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K